Dubai Investments takes 100% control of Globalpharma

Company buys back 66% stake that it divested five years ago to French pharma giant Sanofi

Image used for illustrative purpose. Surgeon and nurse walking and talking in hospital corridor

Image used for illustrative purpose. Surgeon and nurse walking and talking in hospital corridor

Getty Images

Dubai Investments PJSC announced on Thursday it has acquired a 66 percent stake in local pharmaceutical company Globalpharma, bringing its ownership in the company to 100 percent.

Globalpharma, headquartered in Dubai Investments Park, is a manufacturer of generic medicines and has a regional footprint, according to the press statement issued by Dubai Investments.

Dubai Investments, which is listed on the Dubai Financial Market (DFM), said the acquisition was made through Dubai Investments Industries, without disclosing the name of the party from which the stake was acquired.

Dubai Investments had previously sold a 66 percent stake in the company in 2014, retaining the remaining 34 percent, the statement noted.

In October 2014, the company said in a statement filed with DFM that French pharma company Sanofi had acquired a significant stake in Globalpharma from Dubai Investments. It had noted then that Globalpharma would be integrated as a Sanofi Company to become the platform to manufacture and promote the generics portfolio of Sanofi in Middle East markets.

Managing director and CEO Khalid Bin Kalban was quoted as saying in the statement issued on Thursday that the original investment in Globalpharma was “well timed and good for the growth of the healthcare sector in the UAE and region”.

“We see the strategic benefit for making this acquisition. It forms part of the Dubai Investments growth strategy, and underscores our commitment to creating more value for our shareholders,” he said.

Dubai Investments’ healthcare portfolio includes different stakes in KCH Healthcare, Clemenceau Medical Centre, and tie-ups with hospital operators such as NMC in Dubai Investments Park and Mirdif Hills.

Globalpharma manufactures and markets pharmaceutical products under CGMP (Current Good Manufacturing Practice) conditions in more than 14 countries across the Middle East and neighbouring markets.

(Writing by Anoop Menon; Editing by Michael Fahy)


Our Standards: The Thomson Reuters Trust Principles

Disclaimer: This article is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Read our full disclaimer policy here.

For more data, analytics, tools and news on projects in the Middle East visit the Thomson Reuters Projects portal

© Thomson Reuters Projects News 2019

More From GCC